Letter to the editor

Clinical Therapeutics

Volumn 26, Issue 5, 2004, Pages 801-802

  Gervasoni, M ^a   Pirola, R ^a   Bareggi, S R ^a   Tonello, C ^a   Nisoli, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GENERIC DRUG; PSYCHOTROPIC AGENT;

AREA UNDER THE CURVE; BIOEQUIVALENCE; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG MONITORING; DRUG SOLUBILITY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE COST; HUMAN; LETTER; MENTAL DISEASE; PUBLIC HEALTH SERVICE; QUALITY CONTROL; SUSTAINED DRUG RELEASE; TONIC CLONIC SEIZURE; NOTE; PHARMACOKINETICS;

CARBAMAZEPINE; DRUGS, GENERIC; HUMANS; PSYCHOTROPIC DRUGS; THERAPEUTIC EQUIVALENCY;

EID: 4344681591     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90081-1     Document Type: Letter

References (4)

1. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25:1578-1592.
2. Meyer MC, Straughn AB, Jarvi EJ, et al. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res. 1992;9:1612-1616.
3. Meyer MC, Straughn AB, Mhatre RM, et al. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res. 1998;15:1787-1791.
4. United States Pharmacopoeia. 1994;23:267.